DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 5, 2019, reports significant management changes and provides full-year 2018 financial results for DBV Technologies S.A., a clinical-stage biopharmaceutical company. The company is developing the Viaskin platform for epicutaneous immunotherapy, focusing on food allergies (peanut, milk, egg) and Eosinophilic Esophagitis.
Key Financial Metrics (Full Year 2018)
| Metric | 2018 Value | 2017 Value |
|---|---|---|
| Cash and Cash Equivalents (Dec 31) | €122.8 million | €137.9 million |
| Net Loss | €(166.1) million | €(147.7) million |
| Loss Per Share | €(5.74) | €(5.97) |
| Operating Income | €14.5 million | €11.9 million |
| Research & Development Expenses | €107.2 million | €105.2 million |
| General & Administrative Expenses | €41.4 million | €35.8 million |
| Sales & Marketing Expenses | €32.2 million | €15.8 million |
| Cash Used in Operating Activities | €145.8 million | N/A |
| Cash Provided by Financing Activities | €130.7 million | N/A |
Liquidity: Management stated that cash on hand as of December 31, 2018, is expected to fund operations into the fourth quarter of 2019.
Material Changes vs. Prior Period
- Net Loss: Increased by approximately €18.4 million year-over-year, driven by higher operating expenses.
- Operating Income: Increased by 22.1% to €14.5 million, primarily due to the French Research Tax Credit (CIR) and revenue from a collaboration with Nestlé Health Science.
- Expense Growth:
- Sales & Marketing expenses more than doubled (103.3% increase) due to U.S. headcount expansion and preparation for potential commercialization.
- General & Administrative expenses rose 15.6% due to increased personnel and professional service costs.
- R&D expenses increased slightly (1.9%) reflecting Phase III and Phase I/II clinical trial costs.
- Cash Position: Decreased by €15.1 million compared to the prior year end, despite a €130.7 million capital raise in March 2018.
Guidance, Outlook, and Management Commentary
Operational Outlook: The company plans to resubmit its Biologics License Application (BLA) for Viaskin Peanut to the FDA in the third quarter of 2019. Management is re-focusing operations to transition from late-stage R&D to a potential commercial-stage company.
Management Changes:
- Board of Directors: Michel de Rosen appointed Non-Executive Chairman, succeeding co-founder Dr. Pierre-Henri Benhamou, who retired to the Scientific Advisory Board. CEO Daniel Tassé was appointed to the Board.
- Executive Team: Charles Ruban (COO) and Laurent Martin (CDO) are leaving effective March 15, 2019. Mr. Martin will remain as Responsible Pharmacist. Kevin Trapp (CCO) will now report directly to the CEO. Julie O'Neill will assume Mr. Martin's primary responsibilities.
Risks: The filing highlights risks associated with the FDA review of the BLA, the ability to retain key personnel, and the uncertainties inherent in clinical trials. No products are currently authorized for sale.
Investor Verification Checklist
- Verify the timeline and success probability of the Q3 2019 BLA resubmission for Viaskin Peanut.
- Confirm the impact of the departure of the COO and CDO on ongoing clinical trial execution and regulatory strategy.
- Monitor cash burn rate to ensure the runway extends to Q4 2019 as projected.
- Review the specific terms and revenue recognition of the Nestlé Health Science collaboration.
- Assess the integration of the new leadership structure and reporting lines.